No phaseNot yet recruiting
Leveraging Artificial Intelligence to Prevent Vision Loss From Diabetes
Multicenter National Parallel Cluster Randomized Controlled Superiority Trial Comparing an Artificial Intelligence-Based Screening Strategy to Usual Care for Improving Eye-Care Follow-Up Among Patients With Diabetes (AI-BRIDGE Trial)
- Sponsor
- University of Wisconsin, Madison (Academic or other)
- Enrolment
- 6,900 planned
- Conditions
- Diabetic Retinopathy; Diabetes Mellitus
- Interventions
- AI-BRIDGE; Educational Materials
- Ages
- adults, older adults
- Registry
- NCT06763952
From the registry
This pragmatic clinical trial is being conducted to test the effectiveness of AI-BRIDGE (Artificial Intelligence-Based point of caRe, Incorporating Diagnosis, SchedulinG, and Education), in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 8 primary care clinics. AI-BRIDGE is an implementation program which includes an autonomous AI-based protocol that provides screening for diabetic retinopathy (DR) disease at primary care visits, as well as patient education on disease and, if a patient screens positive for referable DR or has insufficient quality image, or image unobtainable due to other technical issues, or does not get AI-screening for any reason, assistance with scheduling an in-person, follow-up eye-care visit.
Primary outcomes
- Proportion of Participants Who Follow Up With Recommended Eye Care